Praveen Thokala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9154984/publications.pdf

Version: 2024-02-01

77 papers

2,831 citations

236925 25 h-index 51 g-index

82 all docs 82 docs citations

times ranked

82

4050 citing authors

#	Article	IF	CITATIONS
1	Multiple Criteria Decision Analysis for Health Care Decision Making $\hat{s}\in$ "An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 1-13.	0.3	437
2	Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 125-137.	0.3	320
3	Multiple Criteria Decision Analysis for Health Technology Assessment. Value in Health, 2012, 15, 1172-1181.	0.3	231
4	The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model Health Technology Assessment, 2012, 16, 1-470.	2.8	213
5	Cost-Effectiveness Thresholds: the Past, the Present and the Future. Pharmacoeconomics, 2018, 36, 509-522.	3.3	124
6	Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome. Health Technology Assessment, 2013, 17, v-vi, 1-188.	2.8	104
7	Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. Health Technology Assessment, 2013, 17, 1-207, v-vi.	2.8	100
8	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value in Health, 2019, 22, 1283-1288.	0.3	97
9	Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic modelâ€. Age and Ageing, 2013, 42, 14-20.	1.6	82
10	Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2017, 20, 310-319.	0.3	79
11	Interventions to improve patient flow in emergency departments: an umbrella review. Emergency Medicine Journal, 2018, 35, 626-637.	1.0	60
12	Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. International Journal of Geriatric Psychiatry, 2017, 32, 1392-1400.	2.7	56
13	The costâ€effectiveness of realâ€time pulmonary artery pressure monitoring in heart failure patients: a European perspective. European Journal of Heart Failure, 2017, 19, 661-669.	7.1	47
14	Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis. Medical Decision Making, 2021, 41, 801-820.	2.4	43
15	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 2015, 19, 1-102.	2.8	43
16	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open, 2013, 3, e003250.	1.9	41
17	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 2012, 98, 1498-1503.	2.9	40
18	High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-234.	2.8	39

#	Article	IF	CITATIONS
19	The costâ€effectiveness of the Dose Adjustment for Normal Eating (<scp>DAFNE</scp>) structured education programme: an update using the Sheffield TypeÂ1 Diabetes Policy Model. Diabetic Medicine, 2013, 30, 1236-1244.	2.3	37
20	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2018, 21, 1019-1028.	0.3	36
21	Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE). Health Technology Assessment, 2013, 17, v-vi, 1-122.	2.8	36
22	The return of public health to local government in England: changing the parameters of the public health prioritization debate?. Public Health, 2015, 129, 1194-1203.	2.9	35
23	What Influences the Implementation of Shared Decision Making: An Umbrella Review. Patient Education and Counseling, 2020, 103, 2400-2407.	2.2	33
24	Prioritising public health guidance topics in the National Institute for Health and Care Excellence using the Analytic Hierarchy Process. Public Health, 2014, 128, 896-903.	2.9	29
25	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making, 2019, 39, 899-909. Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE)	2.4	28
26	programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. Programme Grants for Applied Research,	1.0	28
27	2014, 2, 1-188. Assessing the costâ€effectiveness of TypeÂ1 diabetes interventions: the Sheffield TypeÂ1 Diabetes Policy Model. Diabetic Medicine, 2014, 31, 477-486.	2.3	27
28	Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings. Cost Effectiveness and Resource Allocation, 2018, 16, 43.	1.5	24
29	Sex differences in national rates of repair of emergency abdominal aortic aneurysm. British Journal of Surgery, 2018, 106, 82-89.	0.3	23
30	Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation, 2020, 18, 41.	1.5	19
31	Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment. Pharmacoeconomics, 2017, 35, 989-1006.	3.3	18
32	Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review. Pharmacoeconomics, 2020, 38, 269-283.	3.3	18
33	Economic, clinical and social impact of simple limbal epithelial transplantation for limbal stem cell deficiency. British Journal of Ophthalmology, 2022, 106, 923-928.	3.9	17
34	Variable-complexity optimization applied to airfoil design. Engineering Optimization, 2007, 39, 271-286.	2.6	16
35	Resource Modelling: The Missing Piece of the HTA Jigsaw?. Pharmacoeconomics, 2015, 33, 193-203.	3.3	14
36	Direct medical costs of diabetes mellitus in the year of mortality and year preceding the year of mortality. Diabetes, Obesity and Metabolism, 2018, 20, 1470-1478.	4.4	14

#	Article	IF	CITATIONS
37	Cost-benefit analysis of introducing next-generation sequencing (metagenomic) pathogen testing in the setting of pyrexia of unknown origin. PLoS ONE, 2018, 13, e0194648.	2.5	13
38	Life cycle cost modelling as an aircraft design support tool. Proceedings of the Institution of Mechanical Engineers, Part G: Journal of Aerospace Engineering, 2010, 224, 477-488.	1.3	12
39	Economic impact of Tegaderm chlorhexidine gluconate (CHG) dressing in critically ill patients. Journal of Infection Prevention, 2016, 17, 216-223.	0.9	11
40	Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisalâ€"An Evidence Review Group Perspective. Pharmacoeconomics, 2016, 34, 741-750.	3.3	11
41	The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 385-394.	4.5	11
42	The economics of cardiac biomarker testing in suspected myocardial infarction. Clinical Biochemistry, 2015, 48, 213-217.	1.9	9
43	The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure. Pilot and Feasibility Studies, 2018, 4, 86.	1.2	9
44	The Effectiveness and Value of Treatments for Spinal Muscular Atrophy. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1300-1306.	0.9	9
45	Scoping Review: Intergenerational Resource Transfer and Possible Enabling Factors. International Journal of Environmental Research and Public Health, 2020, 17, 7868.	2.6	9
46	Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data. Value in Health, 2020, 23, 743-750.	0.3	9
47	The CAPACITI Decision-Support Tool for National Immunization Programs. Value in Health, 2021, 24, 1150-1157.	0.3	9
48	Stakeholder involvement in Multi-Criteria Decision Analysis. Cost Effectiveness and Resource Allocation, 2018, 16, 0.	1.5	8
49	Framework for Aircraft Cost Optimization Using Multidisciplinary Analysis. Journal of Aircraft, 2012, 49, 367-374.	2.4	7
50	Cost-effectiveness of Out-of-Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure. Annals of Emergency Medicine, 2015, 65, 556-563.e6.	0.6	7
51	Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis. Journal of Visualized Experiments, 2020, , .	0.3	7
52	The relationship between chronic kidney disease–associated pruritus and health-related quality of life: a systematic review. CKJ: Clinical Kidney Journal, 2022, 15, 484-499.	2.9	7
53	Using MCDA to generate and interpret evidence to inform local government investment in public health. EURO Journal on Decision Processes, 2016, 4, 161-181.	2.7	6
54	Direct medical costs in the preceding, event and subsequent years of a first severe hypoglycaemia episode requiring hospitalization: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2019, 21, 1330-1339.	4.4	6

#	Article	IF	Citations
55	A role for MCDA to navigate the trade-offs in the National Institute for Health and Care Excellence's public health recommendations. Operations Research for Health Care, 2019, 23, 100179.	1.2	6
56	Is a definitive trial of prehospital continuous positive airway pressure versus standard oxygen therapy for acute respiratory failure indicated? The ACUTE pilot randomised controlled trial. BMJ Open, 2020, 10, e035915.	1.9	6
57	HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1162-1170.	0.9	6
58	Incorporating Preferences and Priorities into MCDA: Selecting an Appropriate Scoring and Weighting Technique., 2017,, 47-66.		4
59	The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease. Medical Decision Making, 2020, 40, 912-923.	2.4	4
60	Prehospital continuous positive airway pressure for acute respiratory failure: the ACUTE feasibility RCT. Health Technology Assessment, 2021, 25, 1-92.	2.8	4
61	Views of stakeholders on factors influencing shared decision-making in the Eastern Mediterranean Region: a systematic review. Eastern Mediterranean Health Journal, 2021, 27, 300-311.	0.8	4
62	Priority setting of vaccine introduction in Bangladesh: a multicriteria decision analysis study. BMJ Open, 2022, 12, e054219.	1.9	4
63	Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. BMJ Open, 2021, 11, e055455.	1.9	4
64	Multi Criteria Decision Analysis Methods In Health Care: Current Status, Good Practice And Future Recommendations. Value in Health, 2014, 17, A34.	0.3	3
65	Healthcare professionals' views on factors influencing shared decisionâ€making in primary health care centres in Saudi Arabia: A qualitative study. Journal of Evaluation in Clinical Practice, 2022, 28, 235-246.	1.8	3
66	The effectiveness and value of belimumab and voclosporin for lupus nephritis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1495-1499.	0.9	2
67	Qualitative exploration of patient flow in a Caribbean emergency department. BMJ Open, 2020, 10, e041422.	1.9	2
68	Topic selection process in health technology assessment agencies around the world: a systematic review. International Journal of Technology Assessment in Health Care, 2022, 38, e19.	0.5	2
69	Simulation-Based Life Cycle Cost Modelling as a Decision Support Tool. , 2007, , .		1
70	Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models. Medical Decision Making, 2015, 35, 872-887.	2.4	1
71	Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models. Medical Decision Making, 2019, 39, 842-856.	2.4	1
72	Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach. International Journal of COPD, 2020, Volume 15, 787-797.	2.3	1

#	Article	IF	CITATIONS
73	Configuration of vascular services: a multiple methods research programme. Programme Grants for Applied Research, 2021, 9, 1-150.	1.0	1
74	MCDA for Resource Allocation at a Local Level: An Application in the UK., 2017,, 175-198.		1
75	Cost-effectiveness of out-of-hospital continuous positive airway pressure for acute respiratory failure: decision analytic modelling using data from a feasibility trial. BMC Emergency Medicine, 2021, 21, 13.	1.9	0
76	A review of public health economic modelling in the National Institute for Health and Care Excellence (NICE). HRB Open Research, 0, 3, 30.	0.6	0
77	ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. Applied Health Economics and Health Policy, 2022, , .	2.1	0